Abstract
Sporadic inclusion body myositis (sIBM) is a common age-related inflammatory myopathy characterized by the presence of intracellular inclusions that contain the amyloid-β (Aβ) peptide, a derivative of the amyloid precursor protein (APP). Aβ is believed to cause Alzheimer's disease (AD), suggesting that a link may exist between the two diseases. If AD and sIBM are linked, then treatments that lower Aβ in brain may prove useful for sIBM. To test this hypothesis, transgenic mice that overexpress APP in skeletal muscle were treated for 6. months with a variety of nonsteroidal anti-inflammatory drugs (NSAIDs; naproxen, ibuprofen, carprofen or R-flurbiprofen), a subset of which reduce Aβ in brain and cultured cells. Only ibuprofen lowered Aβ in muscle, and this was not accompanied by corresponding improvements in phenotype. These results indicate that the effects of NSAIDs in the brain may be different from other tissues and that Aβ alone cannot account for skeletal muscle dysfunction in these mice.
Original language | English |
---|---|
Pages (from-to) | 449-456 |
Number of pages | 8 |
Journal | Neurobiology of Disease |
Volume | 39 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2010 |
Bibliographical note
Funding Information:Funding was provided by the NIH ( NS058382 , AG005119 , RR020171 , and HL086341 ) and the Myositis Association . All work was approved by the University of Kentucky IACUC. Thanks to Ela Patel (University of Kentucky) for assistance with the histology and Dr. Elizabeth Head (University of Kentucky) for helpful discussion. Additional thanks to Dr. Todd Golde (Mayo Clinic Jacksonville) for providing antibodies and Dr. Frank M. LaFerla (University of California at Irvine) for providing the T7A6 mouse line.
Keywords
- Alzheimer's disease
- Amyloid
- Amyloid-β precursor protein
- Inflammation
- Sporadic inclusion body myositis
ASJC Scopus subject areas
- Neurology